nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2012 | Image of the Month

[⁶⁸Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with ¹⁸F-FECH

verfasst von: A. Afshar-Oromieh, U. Haberkorn, M. Eder, M. Eisenhut, CM. Zechmann

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Excerpt

Prostate-specific membrane antigen (PSMA) is a cell surface protein, which is expressed at higher levels in prostate cancer compared to other tissues. This protein provides a promising target for specific imaging and therapy due to its transmembrane location and internalization after ligand binding [1]. PSMA is also expressed in the neovasculature of many solid tumours [2, 3]. Recently procedures have been developed to label PSMA with ⁶⁸Ga and ¹²⁴I for positron emission tomography (PET) imaging [4, 5]. …

Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528–39.PubMedCrossRef

Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674–81.PubMed

Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192–8.PubMed

Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009;69(17):6932–40.PubMedCrossRef

Eder M, Schäfer M, Bauder-Wüst U, Wängler C, Mier W, Haberkorn U, Eisenhut M. The ⁶⁸Ga-complex lipophilicity and the targeting property of a urea based PSMA inhibitor for PET imaging. Bioconjug Chem 2011, in revision.

Titel: [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH
verfasst von: A. Afshar-Oromieh
U. Haberkorn
M. Eder
M. Eisenhut
CM. Zechmann
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2069-0

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Marie Claire Cantone and Christoph Hoeschen (eds): Radiation Physics for Nuclear Medicine

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET

Quantification of myocardial blood flow with 82Rb positron emission tomography: clinical validation with 15O-water

Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans

18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size